Disorders

Speaking to Medscape about PTSD, Jeffrey Lieberman likens our current treatments with SSRIs, tricyclics and therapy to "treating tuberculous by putting people in sanitariums or polio with iron lungs, or Alzheimer's disease with these cholinomimetic drugs.” "They are symptom-improving, but they're not disease-modifying,” he adds. “They're just not sufficient…”

According to the CDC, January is National Birth Defects Prevention Month. New research continues to link various SSRI antidepressants with birth defects and neurological abnormalities in newborns. The latest study to examine this topic, a meta-analysis led by Dr. Anick Bérard, found a 23% increased risk for birth defects, and a 28% increased risk for heart problems, in the infants of women who took the SSRI Paxil (paroxetine) during their first trimester.

“Those who possess the data control the story.” In the wake of the reanalysis of the infamous Study 329, where scientific data claiming the antidepressant Paxil was safe and effective for teens was egregiously manipulated, researchers are pushing for open access to raw data. “The issue here, scientists argue, is that without independent confirmation, it becomes too easy to manipulate data.”

Martha Rosenberg calls the reanalysis of Paxil and Study 329 “a victory for safety activists, medical reporters, the public and freedom of the press.” But, she warns, “many pro-pill doctors continue to fight evidence of Paxil’s suicide risks and similar SSRIs.”

For three days in December, I was fortunate enough to attend the Hearing Voices Facilitator Training held in Portland, OR. This training expanded my understanding of the voice hearing experience and equipped me with a number of tools to use in facilitating hearing voices support groups. Grounded in a feeling of community, the training was dynamic, emotionally therapeutic, and educational all at the same time – a crystal clear example of how support groups themselves might manifest in the lives of their members.

On his website, Dr. Nardo details the hidden risks and bad science behind the growing practice of using atypical antipsychotics to augment antidepressant treatment for severe depression. The story of Atypical Antipsychotic Augmentation of Treatment Resistant Depression is a “prime example” “to illustrate how commercial interests have invaded medical practice.” “Besides the obvious dangers of the Metabolic Syndrome and Tardive Dyskinesia, these drugs don’t really do what they’re advertised to do – make the antidepressants work a lot better.”

“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?

Readers respond to the New York Times article, “The Treatment of Choice,” about innovative programs for psychosis and schizophrenia that involve patients and their families in treatment decisions. “Narratives of success counter a drumbeat of faulty links of mental illness and violence, inaccuracies which serve only to further stigmatize and isolate individuals with psychiatric illness.”

An international group of researchers from multiple disciplines has published a historical, qualitative, and quantitative investigation into voice-hearing in women. The interdisciplinary project, freely available from Frontiers in Psychiatry, explores how sexism, exploitation, and oppression bear on women’s’ experiences of hearing voices.

Felice J. Freyer for the Boston Globe reports on a new study of chronic pain treatment. “More than 90 percent of people who survived...

When former NIMH chief Dr. Thomas Insel speaks, people listen. Dr. Insel famously criticized the DSM a couple of years ago for its lack of reliability. He notably broke ranks with the APA by saying there were no bio-markers, blood tests, genetic tests or imaging tests that could verify or establish a DSM diagnosis of schizophrenia, bipolar or schizoaffective disorder. However in a new article he announces research that claims to have found bona-fide physiological markers that identify specific "biotypes" of psychosis. This system could, purportedly, identify a person as possessing a specific biotype of psychosis, instead of a DSM-category diagnosis.

Stimulant medications like Ritalin and Adderall, often prescribed to treat children diagnosed with ADHD, are known to cause hallucinations and psychotic symptoms. Until recently these adverse effects were considered to be rare. A new study to be published in the January issue of Pediatrics challenges this belief, however, and finds that many more children may be experiencing psychotic symptoms as a result of these drugs than previously acknowledged.

We now have only 89 days to respond to Docket No. FDA-2014-N-1210. Tell the FDA no to the down-classification of shock devices. Tell the FDA exactly how subjective and damaging the terms “treatment-resistant” and “require rapid response” are, and how they fail as legitimate medical concepts. The known risks of electroshock should not be ignored because one has been psychiatrically labeled.

“Suicide rates in the United States have been rising, especially among veterans and members of the armed forces. Traditional assumptions about why people kill themselves have not led to effective strategies for suicide prevention,” psychologist Craig Bryan tells Science News. “So in recent years, psychologists and others have been reconsidering basic beliefs about why people carry out the ultimate act of self-destruction.”

When I wrote Anatomy of an Epidemic, one of my foremost hopes was that it would prompt mainstream researchers to revisit the scientific literature. Was there evidence that any class of psychiatric medications—antipsychotics, antidepressants, stimulants, benzodiazepines, and so forth—provided a long-term benefit? Now epidemiologists at Columbia University and City College of New York have reported that they have done such an investigation about antipsychotics, and their bottom-line finding can be summed up in this way: Psychiatry’s “evidence base” for long-term use of these drugs does not exist.

Researchers from the City College of New York and Columbia University published a study this month testing the hypothesis that people diagnosed with schizophrenia treated long-term with antipsychotic drugs have worse outcomes than patients with no exposure to these drugs. They concluded that there is not a sufficient evidence base for the standard practice of long-term use of antipsychotic medications.

Listen: NPR’s On Point with Tom Ashbrook discusses the new book “Moody Bitches: The Truth About the Drugs You’re Taking, The Sleep You’re Missing, the Sex You’re Not Having and What’s Really Making You Crazy,” by the psychiatrist Julie Holland.

Benedict Carey at the New York Times covers the push for new programs that emphasize supportive services, therapy, school and work assistance, and family education, rather than simply drug treatment.

The Food and Drug Administration (FDA) is attempting to reclassify the electroconvulsive therapy (ECT) device for use in treating severe depression (MDE) or bipolar “disorder” (BPD). The device is currently a class III device and the proposal is to make it a class II device.

Children of parents who suffer from depression have a severely heightened risk of mental health problems, but new research points to several factors that seem to strengthen young peoples’ resilience and predict good mental health.

Miriam Stoppard writes an opinion piece on the lack of good research on Ritalin, a drug often used for ADHD, and discusses the latest Cochrane review which found a high percentage of side-effects in children. Despite the lack of quality evidence, “NHS figures show that nearly one million ADHD prescriptions were handed out last year in England – a number that has more than doubled in 10 years.”

We are profoundly social beings living not as isolated individuals but as integral members of interdependent social systems—our nuclear family system, and the broader social systems of extended family, peers, our community and the broader society. Therefore, psychosis and other forms of human distress often deemed “mental illness” are best seen not so much as something intrinsically “wrong” or “diseased” within the particular individual who is most exhibiting that distress, but rather as systemic problems that are merely being channeled through this individual.

In October of 2013, I wrote a blog on the Foundation for Excellence website (‘The Story of My Perfectly Wonderful Children and the Change WE Need to Make in the World to Save Them’) shortly after finding out that my son’s guidance counselor suggested he (then 10) consider ‘distraction meds’ to aid in his school performance. If I could sit every member of this school system down right now and ask them all my most burning questions, they would be: Do you want to be a tool of the system? The one who knows all the rules and holds all the lines? That says 'no, we can't do that', just because that's the way it is? Or do you want to be a guide through all that mess?

A new NIH-funded study suggests that children from low-income environments are more likely to have neurological impairments. The researchers claim that these neurodevelopmental issues are “distinct from the risk of cognitive and emotional delays known to accompany early-life poverty.”

“The paper, The  psychopathology of James Bond, and its implications for the revision of the DSM-007, has just won first prize in the Australian Medical Journal's...